C. difficile

News

Nestle bids to take control of Seres’ C diff drug Vowst

Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upg

R&D

Why gut bacteria is the next frontier in medicine

Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.

News

Vedanta scores $106.5m to take microbiome drug into ph3

In the face of a challenging biotech financing environment, Vedanta Bio has ra

News

FDA accepts review of SeresTx BLA for oral microbiome therap...

The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral

Nestle bids to take control of Seres’ C diff drug Vowst

Why gut bacteria is the next frontier in medicine

Vedanta scores $106.5m to take microbiome drug into ph3

FDA accepts review of SeresTx BLA for oral microbiome therap...

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

C. difficile

Editor's Picks